S162L (p.Ser162Leu) variant of NRXN2 (Neurexin-2)
S162L (p.Ser162Leu) in NRXN2 (Neurexin-2) is a missense change. Clinical records from UniProt describe it as variant assessed as somatic; moderate impact. The available variant effect predictions contribute to a CATVariant prioritization score of 0.64 / 1. The record also includes population frequency data and structural context.
S162L (p.Ser162Leu) variant details
- p.Ser162Leu
- NCI-TCGA Cosmic COSV5545
- Variant assessed as somatic; moderate impact.
- Missense
- Variant Prioritization Score for Impact Estimate 0.639
- REVEL 0.63
- MetaLR 0.47
- MetaSVM 0.06
- CADD 28.20
- PolyPhen-2 0.59
- SIFT 0.00
- UniProt: Variant assessed as somatic; moderate impact.
- Population evidence available
- Structural context available